Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HSK39297 Tablets in Treatment of Patients With Primary IgAN
NCT07390123Phase 3Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ciprocopan in IgA nephropathy (IgAN), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Apr 2026; status: recruiting.
02
Drugs
ciprocopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07390123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07390123.